Shreyaskumar R. Patel, M.D.
Department of Sarcoma Medical Oncology, Division of Cancer Medicine
About Dr. Patel
I am a Tenured Professor of Medicine and hold the Robert R. Herring Distinguished Professorship in Cancer Research. I also serve as the Medical Director of the Sarcoma Center at the University of Texas MD Anderson Cancer Center in Houston. I graduated from Baroda Medical College in Baroda, India and did my Medical Oncology training at the Mayo Clinic in Rochester, MN. I have authored or co- authored more than 250 articles in various journals and have been section editor for the Sarcoma Section of Current Oncology Reports since 2000. I have also authored or co-authored more than 35 book chapters, including last 7 editions of Harrison’s Textbook of Internal Medicine since 1997. My clinical research interests include systemic therapy for sarcomas, GISTs and other tumors originating in bone and soft tissues. I am a past President of CTOS, a member the Executive Committee and Chair of the Clinical Research Committee of SARC, Chair of the Medical Advisory Board and member of the BOD of the Chordoma Foundation. I have served as the past Program Chair for CTOS and the Sarcoma Track for ASCO.
In the News
Present Title & Affiliation
Primary Appointment
Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston
Robert R. Herring Distinguished Professor of Cancer Research, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Center Medical Director, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1981 | Baroda Medical College, Baroda, IND, MD, Medicine |
| 1977 | M.S. University, Baroda, IND, BS, Pre-Medical |
| 1976 | S. P. University, Vallabh Vidyanagar, IND, BA, Preparatory Science |
Postgraduate Training
| 1987-1990 | Fellowship: Medical Oncology, Mayo Clinic, Rochester, MN |
| 1984-1987 | Clinical Residency, Internal Medicine, Wayne State University, Detroit, MI |
| 1982-1983 | Compulsory Rotating Internship, S.S.G. Hospital, M.S. University, Baroda |
Selected Publications
Peer-Reviewed Articles
- Patel SR, Reichardt P. An updated review of the treatment landscape for advanced gastrointestinal stromal tumors. Cancer 127(13):2187-2195, 2021. e-Pub 2021. PMID: 33974733.
- Jones RL, Herzog TJ, Patel SR, von Mehren M, Schuetze SM, Van Tine BA, Coleman RL, Knoblauch R, Triantos S, Hu P, Shalaby W, McGowan T, Monk BJ, Demetri GD. Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Med 10(11):3565-3574, 2021. e-Pub 2021. PMID: 33960681.
- Chugh R, Ballman KV, Helman LJ, Patel S, Whelan JS, Widemann B, Lu Y, Hawkins DS, Mascarenhas L, Glod JW, Ji J, Zhang Y, Reinke D, Strauss SJ. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer 127(8):1301-1310, 2021. e-Pub 2020. PMID: 33289920.
- George S, Jones RL, Bauer S, Kang YK, Schöffski P, Eskens F, Mir O, Cassier PA, Serrano C, Tap WD, Trent J, Rutkowski P, Patel S, Chawla SP, Meiri E, Gordon M, Zhou T, Roche M, Heinrich MC, von Mehren M. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist 26(4):e639-e649, 2021. e-Pub 2021. PMID: 33453089.
- Tarek N, Said R, Andersen CR, Suki TS, Foglesong J, Herzog CE, Tannir NM, Patel S, Ratan R, Ludwig JA, Daw NC. Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 33050651.
- Jones RL, Maki RG, Patel SR, Wang G, McGowan TA, Shalaby WS, Knoblauch RE, von Mehren M, Demetri GD. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer 125(24):4435-4441, 2019. e-Pub 2019. PMID: 31503332.
- Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer 125(15):2610-2620, 2019. e-Pub 2019. PMID: 31173362.
- Choy E, Ballman K, Chen J, Dickson MA, Chugh R, George S, Okuno S, Pollock R, Patel RM, Hoering A, Patel S. SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. Sarcoma 2018:2068517, 2018. e-Pub 2018. PMID: 30473623.
- Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol, 2017. e-Pub 2017. PMID: 28988646.
- Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387(10028):1629-37, 2016. e-Pub 2016. PMID: 26874885.
- Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 34(8):786-93, 2016. e-Pub 2015. PMID: 26371143.
- Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669):1097-104, 2009. e-Pub 2009. PMID: 19303137.
- Patel S, Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer 44(4):501-9, 2008. e-Pub 2008. PMID: 18234488.
- Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 25(19):2755-63, 2007. PMID: 17602081.
- Patel SR, Papadopolous N, Raymond AK, Donato M, Seong CM, Yasko AW, Lewis VO, Lin PP, Champlin R, Benjamin RS. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. Cancer 101(1):156-63, 2004. PMID: 15222001.
- Trent JC, Beach J, Burgess MA, Papadopolous N, Chen LL, Benjamin RS, Patel SR. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 98(12):2693-9, 2003. PMID: 14669291.
- Pisters PW, Ballo MT, Fenstermacher MJ, Feig BW, Hunt KK, Raymond KA, Burgess MA, Zagars GK, Pollock RE, Benjamin RS, Patel SR. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol 21(16):3092-7, 2003. PMID: 12915599.
- Vadhan-Raj S, Patel SR, Bueso-Ramos C, Folloder J, Papadopolous N, Burgess A, Broemeling LD, Broxmeyer HE, Benjamin RS. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol 21(16):3158-67, 2003. PMID: 12915607.
- Ahmad SA, Patel SR, Ballo MT, Baker TP, Yasko AW, Wang X, Feig BW, Hunt KK, Lin PP, Weber KL, Chen LL, Zagars GK, Pollock RE, Benjamin RS, Pisters PW. Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol 20(2):521-7, 2002. PMID: 11786582.
- Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19(15):3483-9, 2001. PMID: 11481354.
- Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J, Benjamin RS. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 21(3):317-21, 1998. PMID: 9626808.
- Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol 15(6):2378-84, 1997. PMID: 9196153.
- Patel SR, Papadopoulos NE, Plager C, Linke KA, Moseley SH, Spirindonidis CH, Benjamin R. Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. Cancer 78(4):741-4, 1996. PMID: 8756366.
- Patel SR, Burgess MA, Papadopoulos NE, Linke KA, Benjamin RS. Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy. Am J Clin Oncol 18(2):161-3, 1995. PMID: 7900708.
- Patel SR, Burgess MA, Plager C, Papadopoulos NE, Linke KA, Benjamin RS. Myxoid liposarcoma. Experience with chemotherapy. Cancer 74(4):1265-9, 1994. PMID: 8055448.
- Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer 72(11):3244-7, 1993. PMID: 8242548.
Grant & Contract Support
| Title: | Early Therapeutics with Phase II Emphasis |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Title: | An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) |
| Funding Source: | Blueprint Medicines Corp |
| Role: | Principal Investigator |
| Title: | Cediranib, Sunitinib malate |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | A Phase I Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) and other Relapsed and Refractory Solid Tumors |
| Funding Source: | Blueprint Medicines Corp |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified October 30, 2024